Tanabe Mitsubishi Pharma Launches Dual-Action Diabetes Medication “Canaria® Combination OD Tablets” with Enhanced Design Features
Tokyo, Japan – September 2, 2025 – Tanabe Mitsubishi Pharma Corporation is pleased to announce the launch of “Canaria® Combination OD Tablets” (generic name: sitagliptin/empagliflozin), a new prescription medication combining a selective DPP-4 inhibitor and an SGLT2 inhibitor. This innovative dual-action treatment is designed to provide a more comprehensive approach to managing type 2 diabetes.
Canaria® Combination OD Tablets represent a significant advancement in diabetes therapy by offering the combined benefits of two distinct drug classes. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and reduce glucagon secretion in a glucose-dependent manner. Empagliflozin, an SGLT2 inhibitor, functions by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. The synergistic action of these two compounds aims to improve glycemic control more effectively in patients with type 2 diabetes.
A notable feature of the newly launched medication is its thoughtfully designed tablet imprint. Tanabe Mitsubishi Pharma has prioritized patient safety and ease of use by adopting a print design that enhances both the identifiability and visibility of the tablets. This focus on user-centric design is intended to minimize the risk of medication errors and ensure patients can confidently take their prescribed treatment.
The introduction of Canary® Combination OD Tablets underscores Tanabe Mitsubishi Pharma’s ongoing commitment to developing innovative pharmaceutical solutions that address the evolving needs of patients with chronic diseases. The company believes this new medication will be a valuable addition to the treatment armamentarium for type 2 diabetes, contributing to improved patient outcomes and quality of life.
Further details regarding the product’s clinical profile and availability will be communicated through healthcare professionals. Tanabe Mitsubishi Pharma looks forward to providing this important new therapeutic option to patients in need.
【ニュースリリース】選択的DPP-4阻害剤/SGLT2阻害剤 配合剤「カナリアⓇ配合OD錠」発売のお知らせ～識別性、視認性を高めた印字デザインを採用～
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
田辺三菱製薬 published ‘【ニュースリリース】選択的DPP-4阻害剤/SGLT2阻害剤 配合剤「カナリアⓇ配合OD錠」発売のお知らせ～識別性、視認性を高めた印字デザインを採用～’ at 2025-09-02 02:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.